Development of Robust Corneal Biomechanical Biomarkers for Glaucoma Using Brillouin Microscopy

Status: Recruiting
Location: See location...
Intervention Type: Drug, Device
Study Type: Observational
SUMMARY

This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• \- Age 18 years or older

• Diagnosis of primary open angle glaucoma (POAG) or no history of glaucoma (for controls)

• Open angle on gonioscopy (Shaffer grade 3 or 4)

• Best-corrected visual acuity of 20/25 or better

• Refractive error between +3.00 and -5.00 diopters

• No prior use of topical glaucoma medications

• Diagnosis of:

• High Tension Glaucoma (IOP ≥ 22 mmHg on 3 visits)

• Normal Tension Glaucoma (IOP ≤ 21 mmHg on 3 visits)

• OR age-matched control with normal optic nerve and visual fields

Locations
United States
Maryland
University of Maryland School of Medicine
RECRUITING
Baltimore
Contact Information
Primary
Osamah Saeedi, MD
osaeedi@som.umaryland.edu
16672141232
Time Frame
Start Date: 2025-09-01
Estimated Completion Date: 2026-06
Participants
Target number of participants: 60
Treatments
Normal Tension Glaucoma
Newly diagnosed, treatment-naïve subjects with normal tension glaucoma. Brillouin imaging will be performed at baseline, and in a subset receiving IOP-lowering therapy, additional imaging will be performed at 3 and 6 weeks.
High Tension Glaucoma
Newly diagnosed, treatment-naïve subjects with high tension glaucoma. Brillouin imaging will be performed at baseline, and in a subset receiving IOP-lowering therapy, additional imaging will be performed at 3 and 6 weeks.
Control
Age-matched healthy control subjects with no history of glaucoma or IOP-lowering therapy. Brillouin imaging will be performed at a single time point for cross-sectional comparison.
Related Therapeutic Areas
Sponsors
Collaborators: National Eye Institute (NEI)
Leads: University of Maryland, Baltimore

This content was sourced from clinicaltrials.gov